Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

INSANE: 7 - The Real Truth

Health care investors convene in SF

Health care’s business class returned to San Francisco last week for JPMorgan’s annual health care confab

Salon

Want Passive Income in a Bear Market? Check out This Biotech Stock

With the minutes of the latest Fed meeting showing that interest rates will keep increasing this year, the economy is widely expected to enter a recession. Amid the expected downturn this year, it could be wise to buy biotech stock Gilead Sciences (GILD) due to its solid growth prospects and…

StockNews.com

2 Biotech Stocks to Buy Amid a Blazing Hot Run

A rapidly aging population and the rise in lifestyle diseases drive the biotech industry’s growth. Through their cutting-edge research, biotech companies are coming up with new solutions to develop treatments. Given the solid long-term prospects of the industry, it could be wise to buy fundamentally strong biotech stocks Amgen Inc.…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Up More than 19% In 2022, Is Gilead Sciences Still a Buy?

Gilead Sciences (GILD) beat revenue and earnings estimates in the previous quarter and upgraded its guidance for fiscal 2022. Having risen more than 19% year-to-date, is GILD still a buy? Read on to learn our view.

StockNews.com

The week in TV: Brian Cox: How the Other Half Live; I’m a Celebrity…; 1899; Hong Kong’s Fight for Freedom and more

The Succession star rages against inequality; all aboard Netflix’s Victorian steamship horror; Hongkongers turn to violence; and The Handmaid’s Tale is back on track

The Guardian - UK

1 Stock to Buy This Week Following Its Recent Earnings Beat

Biopharmaceutical giant Gilead Sciences (GILD) reported better-than-expected third-quarter earnings and sales and raised its full-year guidance. Analysts see immense growth potential in the company’s HIV and oncology franchises, which should boost its performance in the upcoming quarters. Given its strong earnings, high profitability, discounted valuation, and attractive dividend, we think…

StockNews.com

It’s time for June Osborne to start winning in The Handmaid’s Tale

‘The Handmaid’s Tale’, returning to Channel 4 this weekend, has spent four seasons dragging June into the depths of hell. There’s nothing more to be learnt from her suffering, writes Amanda Whiting

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

U.S. sends experimental antibody, antiviral drug to Uganda for Ebola outbreak

The United States sent Gilead Sciences' remdesivir and Mapp Biopharmaceutical Inc's experimental Ebola antibody drug MBP134 to Uganda last week to help safeguard healthcare workers responding to an outbreak that has infected 60 people and killed 44, U.S. government sources told Reuters.

Reuters

Vietnam Law May Impact Facebook, Twitter; Amazon Has A Sleep Tracker; India Lures Apple, Dell, HP: Top Financial Media Stories Thursday, Sept. 29

Reuters

Benzinga

It's Not Too Late for Investors to Start Buying GILD Stock

Biopharmaceutical giant Gilead Sciences (GILD) has delivered solid segmental sales growth in the last reported quarter. In addition, the company’s various research breakthroughs and drug approvals should further bolster its performance in the coming months. Given its robust profitability and discounted valuation, we think it could be wise to scoop…

StockNews.com

It’s time for June Osborne to start winning in The Handmaid’s Tale

‘The Handmaid’s Tale’ has spent four seasons dragging June into the depths of hell. There’s nothing more to be learnt from her suffering, writes Amanda Whiting

The Independent UK

Democratic candidate compares Florida to ‘Handmaid’s Tale’ in attack on DeSantis

1985 dystopian novel has become shorthand critique of many Republican policies

The Independent UK

New this week: 'The Handmaid’s Tale' and 'Goodnight Mommy'

This week’s new entertainment releases include albums from Little Big Town and Marcus Mumford, “The Handmaid’s Tale” returns with high stakes for the future of Gilead, and twin brothers go to their mother’s house for a stay but find something is off about her in the film “Goodnight Mommy.”

The Independent UK

Television Q&A: What has David Duchovny been up to in recent years?

You have questions. I have some answers.

Tribune News Service

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Everest Medicines Descends To New Depths On String Of Bad News

Key Takeaways: The CEO of Everest Medicines resigned two days after the company announced its loss grew sharply in the first half of the year The company also lost an important potential new revenue source after transferring rights for one of its core products to another company By Emily Chan

The Independent UK

Limited funding hampers charities’ early monkeypox response

Two biopharmaceutical companies will give $5 million and $500,000, respectively, to nonprofit organizations in the United States and abroad that are responding to the growing monkeypox outbreak

Pedestrian.tv

The Handmaid’s Tale S5 Trailer Shows The Chilling Repercussions After Brutal S4 Finale

Shit's about to get real.

Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

1 Biotech Stock Investors Will Want to Buy This Week

Gilead Sciences (GILD), a biopharmaceutical company, reported strong demand across its HIV portfolio and raised its full-year guidance. Given the company’s robust profitability and discounted valuation, we think it could be wise to buy the stock now. Read on….

Reuters

Drugmaker Gilead to help fund monkeypox education for LGBTQ+ groups

Drugmaker Gilead Sciences plans to announce on Tuesday that it will provide up to $5 million in grants to help a coalition of LGBTQ+ and human rights advocacy groups craft public health responses to monkeypox outbreaks, the company said.

Benzinga

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Salon

The GOP's "Gilead Playbook"

We're now living in the aftermath of all that the Trump years unleashed. How do we escape this misogynist madness?

Benzinga

Recap Of Friday's Biotech Catalysts - End Of The Day Summary

Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…

The Independent UK

Margaret Atwood defends ‘I told you so’ mug likening post-Roe America to Handmaid’s Tale

‘The Handmaid’s Tale’ imagines a future in which the US has become a fundamentalist, authoritarian, theocratic regime known as Gilead

Tribune News Service

As drugmakers cut off discounts, providers fret for low-income patients

Hospitals and community and rural health clinics that serve low-income patients say drug manufacturers have threatened their financial stability by dramatically cutting back their participation in a federal drug discount program that saves those health providers millions of dollars a year.

1 … 6 7 8 9

People

Dipanjan BanchurSince

722 stories

Brian Cox

648 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.